Interferon-alpha might increase triglyceride serum levels through the enhancement of hepatic lipogenesis and/or inhibition of the peripheral lipoprotein lipase. Hypertriglyceridemia during interferon-alpha therapy has been only recently described, mostly in patients with previous abnormalities of lipid metabolism. The authors report here a case of a 65-year-old male bearing advanced colon carcinoma who developed hypertriglyceridemia during long-term interferon-alpha treatment in association with 5 fluorouracil administration. Hypertriglyceridemia was maintained within acceptable levels, without adjusting the treatment plan, by an appropriate diet and gemfibrosil administration.
BeutlerB.A., CeramiA.: Cachectin: more than a tumor necrosis factor.N. Engl. J. Med., 316: 379–385, 1987.
3.
BrunzelJ.D.: The hyperlipoproteinemias. In: Cecil Text Book of Medicine.WyngaardenJ.B., SmithL.H. (Eds.). W.B. Saunders, Philadelphia, London, Tokyo,1985.
4.
DinarelloS.A.: Interleukin-1 and its biologically related cytokines.Adv. Immunol., 44: 153–205, 1989.
5.
DixonR.M., BordenE.C., KeimN.L., AndersonS., SpennettaT.L., TormeyD.C., ShragoE.: Decreases in serum highdensity-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons.Metabolism, 33: 400–404, 1984.
6.
FeingoldK.R., GrunfeldC.: Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo.J. Clin. Invest., 80: 184–190, 1987.
FiserR.H., DennistonJ.C., BeiselW.R., BartelloniP.J.: Infection with Diplococcus pneumoniae and Salmonella typhimurinum in monkeys: changes in plasma lipids and lipoproteins.J. Infect. Dis., 125: 54–60, 1972.
GrunfeldC., SouedM., AdiS., MoserA.H., DinarelloA.C., FeingoldK.R.: Evidence of two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-alpha.Endocrinology, 127: 46–54, 1990.
11.
GrunfeldC., KotierD.P., ShigenagaJ.K., DoerrlerW., TierneyA., WangJ., PiersonR., FeingoldK.R.: Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.Am. J. Med., 90: 154–162, 1991.
12.
KeayS., GrossbergS.E.: Interferon inhibtis the conversion of 3T3-L1 mouse fibroblasts into adipocytes.Proc. Natl. Acad. Sci. USA, 77: 4099–4103, 1980.
13.
LeesR.S., FisherR.H.Jr., BeiselW.R., BartelloniP.J.: Effects of an experimental viral infection on plasma lipid and lipoprotein metabolism.Metabolism, 21: 825–833, 1972.
14.
MassaroE.R., BordenE.C., HawkinsM.J., WiebeD.A., ShragoE.: Effects of recombinant interferon-alpha-2 treatment upon lipid concentrations and lipoprotein composition.J. Interferon. Res., 6: 655–662, 1986.
15.
ObergK., ErikssonB.: Medical treatment of neuroendocrine gut and pancreatic tumors.Acta Oncol., 28: 425–431, 1989.
16.
OppenheimJ.J., CohenS.: Interleukins, lymphokines, and cytokines. In: Proceedings of the Third International Lymphokine Workshop, pp. 1–799, Academic Press, New York, 1983.
17.
PattonJ.S., ShepardH.M., WilkingH., LewisG., AggarwalB.B., EessaluT.E., GavinL.A., GrunfeldC.: Interferons and tumor necrosis factor have similar catabolic effects on 3T3-L1 cells.Proc. Natl. Acad. Sci. Usa, 83: 8313–8317, 1986.
18.
PriceS.R., MizelS.B., PekalaP.H.: Regulation of lipoprotein lipase synthesis and 3T3-L1 cell metabolism by recombinant interleukin-1. Biochim.Biophys. Acta, 889: 374–381, 1986.
19.
RosembergS.A., LongoD.L., LotzeM.T.: Principles and application of biologic therapy. In: Cancer, Principles and Practice of Oncology.De VitaV.T.Jr., HellmanS., RosembergS.A. (Eds.), pp. 301–347, Lippincott, Philadelphia, 1989.
20.
WadlerS., WiernikP.H.: Clinical update on the role of fluorouracil and recombinant interferon alpha-2a in the treatment of colorectal carcinoma.Semin. Oncol., 1 (Suppl. 1): 16–21, 1990.
